Bank Julius Baer & Co
AXSM icon

Bank Julius Baer & Co’s Axsome Therapeutics AXSM Stock Holding History

Bank Julius Baer & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-450
Closed -$17K – 602
2021
Q4 		$17K Buy
+450
New +$16.6K ﹤0.01% 751
2020
Q2 		– Sell
-7,427
Closed -$436K – 691
2020
Q1 		$436K Buy
+7,427
New +$605K 0.01% 330

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Bank Julius Baer & Co's AXSM Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Axsome Therapeutics (AXSM) in Q1 2022, closing a stake of 450 shares — an estimated $17K sold.

Bank Julius Baer & Co first reported a position in AXSM in Q1 2020 and held it in 2 quarters. The position peaked at $436K in Q1 2020. 175 funds tracked by Wall St. Rank hold AXSM as of Q1 2022.

  • Bank Julius Baer & Co reported no remaining Axsome Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 450 Axsome Therapeutics shares in Q1 2022, an estimated $17K.
  • Bank Julius Baer & Co first reported a position in Axsome Therapeutics in Q1 2020 and held it in 2 quarters.
  • Bank Julius Baer & Co's Axsome Therapeutics position peaked at $436K in Q1 2020.
  • 175 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.